Braveheart Bio (BRVE) Director David Lubner Buys $1.0M Stock

What Happened

• David Charles Lubner, a director of Braveheart Bio, made an open‑market purchase of 55,555 common shares on 2026-08-07 at $18.00 per share for a total of $999,990. He was also granted a derivative award of 60,000 shares (recorded as a $0 price award/option) on 2026-08-05.

Key Details

• Purchases: 55,555 shares on 2026-08-07 at $18.00 each = $999,990 (transaction code P).
• Award/derivative: 60,000 shares granted on 2026-08-05 at $0.00 (transaction code A); filing characterizes this as a share option/award.
• Vesting note (from filing): 1/36 of the shares subject to the option vest in equal monthly installments beginning on the monthly anniversary of July 23, 2026, subject to continuous service (Footnote F1).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on 2026-08-07 for transactions dated 2026-08-05 and 2026-08-07 (filed within the standard 2‑business‑day window).

Context

• The open‑market purchase is an immediate buy of company stock (cash purchase). The 60,000‑share award is a derivative option that vests over ~36 months and is not fully exercisable until vested per the schedule. Purchases by insiders are often watched by investors, but filings are factual disclosures and do not state the insider’s motivations.